These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32708551)

  • 1. Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression.
    Luca BA; Moulton V; Ellis C; Connell SP; Brewer DS; Cooper CS
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32708551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DESNT: A Poor Prognosis Category of Human Prostate Cancer.
    Luca BA; Brewer DS; Edwards DR; Edwards S; Whitaker HC; Merson S; Dennis N; Cooper RA; Hazell S; Warren AY; ; Eeles R; Lynch AG; Ross-Adams H; Lamb AD; Neal DE; Sethia K; Mills RD; Ball RY; Curley H; Clark J; Moulton V; Cooper CS
    Eur Urol Focus; 2018 Dec; 4(6):842-850. PubMed ID: 28753852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
    Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
    Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel stratification framework for predicting outcome in patients with prostate cancer.
    Luca BA; Moulton V; Ellis C; Edwards DR; Campbell C; Cooper RA; Clark J; Brewer DS; Cooper CS
    Br J Cancer; 2020 May; 122(10):1467-1476. PubMed ID: 32203215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HES6 promotes prostate cancer aggressiveness independently of Notch signalling.
    Carvalho FL; Marchionni L; Gupta A; Kummangal BA; Schaeffer EM; Ross AE; Berman DM
    J Cell Mol Med; 2015 Jul; 19(7):1624-36. PubMed ID: 25864518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a predictive model for stromal content in prostate cancer samples to improve signature performance.
    Boufaied N; Takhar M; Nash C; Erho N; Bismar TA; Davicioni E; Thomson AA
    J Pathol; 2019 Dec; 249(4):411-424. PubMed ID: 31206668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
    Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases.
    Ong CW; Maxwell P; Alvi MA; McQuaid S; Waugh D; Mills I; Salto-Tellez M
    J Pathol Clin Res; 2018 Apr; 4(2):103-113. PubMed ID: 29665325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining Molecular Subtypes with Multivariable Clinical Models Has the Potential to Improve Prediction of Treatment Outcomes in Prostate Cancer at Diagnosis.
    Wardale L; Cardenas R; Gnanapragasam VJ; Cooper CS; Clark J; Brewer DS
    Curr Oncol; 2022 Dec; 30(1):157-170. PubMed ID: 36661662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer.
    Zhao SG; Evans JR; Kothari V; Sun G; Larm A; Mondine V; Schaeffer EM; Ross AE; Klein EA; Den RB; Dicker AP; Karnes RJ; Erho N; Nguyen PL; Davicioni E; Feng FY
    Clin Cancer Res; 2016 Apr; 22(7):1777-86. PubMed ID: 26631616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.
    Johnston WL; Catton CN; Swallow CJ
    BMC Urol; 2019 Jan; 19(1):4. PubMed ID: 30616540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of PCS and PAM50 prostate cancer classification schemes.
    Yoon J; Kim M; Posadas EM; Freedland SJ; Liu Y; Davicioni E; Den RB; Trock BJ; Karnes RJ; Klein EA; Freeman MR; You S
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):733-742. PubMed ID: 33531653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reference-free transcriptome signatures for prostate cancer prognosis.
    Nguyen HTN; Xue H; Firlej V; Ponty Y; Gallopin M; Gautheret D
    BMC Cancer; 2021 Apr; 21(1):394. PubMed ID: 33845808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer.
    Cava C; Bertoli G; Colaprico A; Bontempi G; Mauri G; Castiglioni I
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.
    Chen JL; Li J; Stadler WM; Lussier YA
    J Am Med Inform Assoc; 2011; 18(4):392-402. PubMed ID: 21672909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account.
    Chen X; Xu S; McClelland M; Rahmatpanah F; Sawyers A; Jia Z; Mercola D
    PLoS One; 2012; 7(9):e45178. PubMed ID: 23028830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.